Company intelligence / Profile preview

IntraClear Biologics

Tallinn, Harju, Estoniaintraclearbiologics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

IntraClear Biologics is an early-stage Estonian biotech company focused on developing gene therapies to remove intracellular waste products like lipofuscin. Their approach aims to address the root causes of age-related diseases by enabling cells to synthesize enzymes that degrade these harmful accumulations. The company is still in preclinical development and has not yet reported clinical results or advanced candidates into human trials

Therapeutic areas: Neurology
Modalities: Gene therapyProteinsEnzymes
Industry: Biotech

Partnerships

Potential partnership/licensing discussions with Entos Pharmaceuticals regarding Fusogenix delivery technology; no formal partnerships announced as of latest updates

Beyond the preview

Go deeper on IntraClear Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntraClear Biologics.

Explore the full profile